Nan Fung Group
VC Fund
Central, Hong Kong
Nan Fung Group is a property developer with global interests in property markets, financial investments, shipping, and hotel investment.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Nan Fung Group invests in
Stages Nan Fung Group invests in
Countries Nan Fung Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $18M–$66M
Investment Focus
Industry
- Health Care 4 (40%)
- Biotechnology 4 (40%)
- Pharmaceutical 3 (30%)
- Medical Device 2 (20%)
- Gaming 1 (10%)
Stage
- Series B 5 (50%)
- Series A 2 (20%)
- Series C 2 (20%)
- Venture - Series Unknown 1 (10%)
Country
- United States 5 (50%)
- China 2 (20%)
- Hong Kong 2 (20%)
- Canada 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anthony Leung
Group Chairman and CEO
|
Group Chairman and CEO | Total investments: 0 | Find email | |
Chen Din Hwa
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Asian University Basketball League is a pioneering pan-regional basketball competition. | Series A / Apr 09, 2026 | ||
| VSPN is an internet sports and cultural media company that focuses its business on e-sports. It provides core marketing and entertainment content operations as its core business, providing brand marketing, artist brokerage, e-sports TV, and e-sports venues.Founded in 2015, Quantum Sports VSPN (Versus Programming Network) and is based in Shanghai,China. | $60M / Series B / Jan 21, 2021 | ||
| FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together withworld-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years. | $66M / Series B / May 16, 2018 | ||
| Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $66M / Series B / May 16, 2018 | ||
| Baletoo.com is a C2C real estate platform that provides rentals & information to tenants, homeowners, and real estate agents. | Series C / May 10, 2018 | ||
| Boxful is more than just storage. They are about creating a lifestyle where space isn’t a luxury – it’s flexible and right at your fingertips. Boxful was founded on the belief that storage should be simple, affordable, and secure.They created a service that allows you to store and seamlessly manage your belongings from your computer or mobiledevice, and know that they’re just a speedy delivery away. Your home is for living and they give you the freedom to de-clutter while keeping the things that matter. | $18M / Series B / Dec 06, 2017 | ||
| Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarilyfor local diseases or for complications associated with medical device implants, surgical interventions and acute injury. | Venture - Series Unknown / Mar 21, 2017 | ||
| Surkus is a product discovery app where DTC businesses can source feedback and content creation from consumers by offering free or heavily discounted products. | Series A / Jan 01, 2017 | ||
| We have developed a high-sensitivity next-generation sequencing-based system for the the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood.Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques inmolecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level. | $40M / Series B / Jun 01, 2016 | ||
| Bolt is a materials company that invents and scales materials that put the planet on a path towards a better future. Biofabricated silk fibers MicrosilkTM - based on proteins found in nature, produced using Bolt Threads proprietary technology and revolutionary bioengineering concepts. Next-generation of performance fibers, fabrics and luxuryproducts that represent cutting-edge technology in science, while raising the bar for quality, performance, and design. | $50M / Series C / May 11, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Nan Fung Group invest in?
Nan Fung Group invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Nan Fung Group invest in?
Nan Fung Group typically joins rounds of $18M–$66M at Series B. These are whole funding-round sizes, not Nan Fung Group's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Nan Fung Group took part in.
How do I contact Nan Fung Group?
Public channels for Nan Fung Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nan Fung Group?
The team at Nan Fung Group includes Anthony Leung (Group Chairman and CEO) and Chen Din Hwa (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
